Skip to content

Study · Randomized controlled trial · n = 12 · 2016

4 results

Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.

Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Diamant M, Pieters-van den Bos IC, van Raalte DH, Cahen DL

Diabetes, obesity & metabolism13 Jan 2016Cited by 4 (Europe PMC)

PMID26640129 (opens in a new tab)DOI10.1111/dom.12612 (opens in a new tab)PepBankPUB-26640129
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with type 2 diabetes, exenatide did not change secretin-stimulated pancreatic excretion volume compared with placebo.

    In plain wordsIn men with type 2 diabetes, exenatide did not change pancreatic fluid output compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSecretin-stimulated pancreatic excretion volume
    Study

    n = 12

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Pancreatic excretion volume
    142.2 ml
    exenatide
    Pancreatic excretion volume
    142.6 ml
    placebo

    Source sentences

    Summary
    Exenatide did not change secretin-stimulated pancreatic excretion volume, as compared with placebo (mean ± standard error of the mean 142.2 ± 15.6 ml vs 142.6 ± 8.5 ml, respectively; p = 0.590).
    3 context sentences
    Summary · context
    This was a randomized, placebo-controlled, double-blind, crossover study in 12 male patients with type 2 diabetes, treated with oral glucose-lowering agents.
    Summary · context
    On two separate occasions, exenatide or placebo (saline 0.9%) were administered intravenously, in randomized order.
    Summary · context
    The primary outcome measure was defined as secretin-stimulated pancreatic excretion volume.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men with type 2 diabetes, exenatide did not change maximum pancreatic secretion speed compared with placebo.

    In plain wordsIn men with type 2 diabetes, exenatide did not change maximum pancreatic secretion speed compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMaximum secretion speed
    Study

    n = 12

    Comparator
    placebo
    Analysis
    Secondary
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Maximum secretion speed
    33.1
    exenatide
    Maximum secretion speed
    36.9
    placebo

    Source sentences

    Summary
    Also, exenatide did not change the maximum secretion speed (33.1 ± 1.4 vs 36.9 ± 2.2; p = 0.221), nor the time to reach this maximum (both 4 min 30 s).
    3 context sentences
    Summary · context
    This was a randomized, placebo-controlled, double-blind, crossover study in 12 male patients with type 2 diabetes, treated with oral glucose-lowering agents.
    Summary · context
    On two separate occasions, exenatide or placebo (saline 0.9%) were administered intravenously, in randomized order.
    Summary · context
    Secondary outcome measures were maximum secretion speed and the time to reach this maximum.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In men with type 2 diabetes, exenatide did not change time to maximum secretion speed compared with placebo.

    In plain wordsIn men with type 2 diabetes, exenatide did not change time to maximum pancreatic secretion speed compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeTime to maximum secretion speed
    Study

    n = 12

    Comparator
    placebo
    Analysis
    Secondary
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Time to maximum secretion (minute component)
    4 min
    Both groups, total time 4 min 30 s
    Time to maximum secretion (second component)
    30 s
    Both groups, total time 4 min 30 s

    Source sentences

    Summary
    Also, exenatide did not change the maximum secretion speed (33.1 ± 1.4 vs 36.9 ± 2.2; p = 0.221), nor the time to reach this maximum (both 4 min 30 s).
    3 context sentences
    Summary · context
    This was a randomized, placebo-controlled, double-blind, crossover study in 12 male patients with type 2 diabetes, treated with oral glucose-lowering agents.
    Summary · context
    On two separate occasions, exenatide or placebo (saline 0.9%) were administered intravenously, in randomized order.
    Summary · context
    Secondary outcome measures were maximum secretion speed and the time to reach this maximum.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In men with type 2 diabetes, pancreatic duct diameter did not differ between exenatide and placebo.

    In plain wordsIn men with type 2 diabetes, pancreatic duct diameter did not differ between exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePancreatic duct diameter
    Study

    n = 12

    Comparator
    placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    No differences in PD diameter were observed between the two groups.
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, double-blind, crossover study in 12 male patients with type 2 diabetes, treated with oral glucose-lowering agents.
    Summary · context
    On two separate occasions, exenatide or placebo (saline 0.9%) were administered intravenously, in randomized order.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.